Rafiq Hasan

CEO at Complement Therapeutics

Rafiq has pursued a highly successful career in the pharma industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as SVP and Global Head of Ophthalmology at Bayer, Rafiq grew the business of Eylea® from launch to over USD 2.5bn in 5 years, including its launch in 5 indications in 3 years.

Timeline

  • CEO

    Current role